9969 — InnoCare Pharma Income Statement
0.000.00%
Last trade - 00:00
- HK$12.16bn
- HK$5.71bn
- CNY738.54m
- 11
- 12
- 87
- 25
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.25 | 1.36 | 1,043 | 625 | 739 |
Cost of Revenue | |||||
Gross Profit | 1.25 | 1.36 | 977 | 482 | 610 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,152 | 392 | 1,064 | 1,519 | 1,390 |
Operating Profit | -2,151 | -391 | -21.5 | -893 | -651 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,150 | -392 | -20.1 | -894 | -644 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,150 | -392 | -66.7 | -894 | -646 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -2,141 | -391 | -64.5 | -887 | -631 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2,141 | -391 | -64.5 | -887 | -631 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.21 | -0.222 | -0.037 | -0.503 | -0.37 |
Dividends per Share |